Conference Presentation: Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial

In this randomized trial, polymyxin B hemoperfusion treatment plus conventional medical therapy did not reduce mortality at 28 days compared with sham treatment plus conventional medical therapy among patients with septic shock and high endotoxin activity. Phillip Dellinger, MD, MSc, of Cooper University Hospital and Cooper Medical School of Rowan University, Camden, New Jersey, presents findings from the EUPHRATES trial at the European Society of Intensive Care Medicine (ESICM) 31st Annual Congress, LIVES 2018, on October 24 in Paris. Used with permission.